RECEPTA Biopharma

Recepta Biopharma is a biotechnology company focused on developing innovative monoclonal antibody treatments for advanced cervical cancer and other oncology indications. Operating in the biopharmaceutical sector, Recepta Biopharma serves patients with high unmet medical needs, particularly those with relapsed or refractory metastatic cervical cancer. The company’s business model revolves around the research, development, and commercialization of monoclonal antibody therapies, leveraging cutting-edge scientific advancements to create effective treatments. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies. Recepta Biopharma has received Fast Track designation from the FDA for its lead candidates, balstilimab and zalifrelimab, highlighting the significant potential of its therapeutic pipeline.

Keywords: monoclonal antibodies, cervical cancer, biopharmaceutical, oncology, FDA Fast Track, balstilimab, zalifrelimab, clinical trials, innovative treatments, unmet medical needs.